Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard egg-based quadrivalent vaccine (QIVe) in preventing influenza-like illness
| SUMMIT, N.J., PRNewswire/ --Seqirus a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard egg-based quadrivalent vaccine (QIVe) in preventing influenza-like illness (ILI) captured within primary care visits in people aged 4 years and above during the 2017/18 influenza season in the United States (U.S.), a season characterized by egg-adapted changes.1 The 2017/18 season in the U.S. was considered to be one of the worst in recent years due to the predominance of the H3N2 influenza virus.2 Research has shown that some H3N2 viruses undergo changes when they are grown in eggs, and that these changes may reduce the effectiveness of standard egg-based influenza vaccines in H3N2-dominated seasons. When produced completely outside of the egg-based process, cell-based influenza vaccines avoid egg-adapted changes, which means they may offer a closer match and potentially improved protection compared to standard egg-based options in some seasons.3,4,5,6,7,8 “Real-world evidence is critical in evaluating influenza vaccine effectiveness for continued advances in influenza prevention, and these new data are some of the most robust we have seen to date,” said Russell Basser MD, SVP of Research and Development, Seqirus. “This study, along with other burgeoning evidence, indicates that cell-based vaccines may result in better influenza-related outcomes compared to standard vaccine options in some seasons, particularly those characterized by egg-adapted changes.” The data from this Seqirus commissioned study, generated from one of the largest electronic medical record (EMR) providers for primary care practices in the U.S., were presented at the recent National Foundation for Infectious Disease (NFID) 2018 Clinical Vaccinology Course. Seqirus studied data from 1,353,862 patient records to determine effectiveness of QIVc to prevent ILI compared to QIVe.1 Developing new and better influenza vaccine technologies is a strategic priority for Seqirus, including further advances in cell-based technology and the use of adjuvants to enhance the immune response. The company has rapidly scaled up cell-based influenza vaccine production over recent years, which has enabled sufficient quantities of the vaccine to be available for real-world effectiveness studies. “The burden and impact of influenza remains an important global healthcare concern and ensuring we have effective vaccines is a public health imperative,” said Gordon Naylor, President, Seqirus. “As a company on the front line of influenza protection, we are committed to developing innovative solutions, like cell-based vaccines, to help reduce deaths and severe illness caused by influenza.” Seqirus produces cell-based influenza vaccines at its Holly Springs facility in North Carolina. The facility was purpose-built in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to combat pandemic influenza threats.9 BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. “BARDA is committed to bringing forth innovation that can save lives. We know that the most effective approach to saving lives from pandemic influenza is to develop innovative technology that is used to combat seasonal influenza,” said BARDA Director Rick Bright, Ph.D. “Today’s announcement further underscores the positive impact public-private partnerships can have on the ability to protect people in our nation and around the world from the devastating impact of influenza.” Seqirus licensed QIVc in 2016 and is supplying over 20 million doses to the U.S. market this season. About the Study1 Real-world data from one of the largest electronic medical record (EMR) providers for primary care practices in the U.S. were obtained between August 1, 2017 and March 31, 2018. Seqirus evaluated these data as a retrospective cohort study which allowed for the estimation of the relative vaccine effectiveness (rVE) of cell-based quadrivalent, inactive influenza vaccine (QIVc) versus egg-based, quadrivalent, inactive influenza vaccine (QIVe). Researchers analyzed EMRs from 92,192 subjects who received a QIVc and 1,255,983 subjects who received a QIVe to determine which vaccine was more effective in preventing influenza-like illness (ILI). While the effectiveness outcome evaluated in this real-world analysis was not polymerase chain reaction (PCR) confirmed, ILI is an effectiveness outcome used by the Centers for Disease Control (CDC) and World Health Organization (WHO) and reflects exposure and outcome experiences during routine clinical practice. The study population included patients ages 4 years and above who received either QIVe or QIVc in primary care, in the U.S., during this period. Exposures (QIVc or QIVe) were derived from recorded immunizations in individual patients EMRs. The rVE estimated from the study’s primary analysis indicated that QIVc was more effective than standard egg-based QIVs in preventing ILI (rVE of 36.2%, 95% CI (26.1,44.9; P<0.001)). Potential study limitations were minimized using stringent quality control of the data set, cross-referencing the exposure classification step, evaluating two different outcomes code sets for ILI, adjusting for key variables and conducting multiple sensitivity analyses.10 About Seasonal Influenza Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people. To reduce the risk of more serious outcomes, such as hospitalization and death, resulting from influenza, the CDC encourages annual vaccination for all individuals aged 6 months and older.11 Because transmission to others may occur one day before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others.12 Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases death.11 The CDC estimates that 959,000 people in the United States were hospitalized due to influenza-related complications during the 2017/18 influenza season.2 Since it takes about 2 weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, it is best that people get vaccinated to help protect them before influenza begins spreading in their community.11 About Seqirus Seqirus is part of CSL Limited (ASX: CSL), headquartered in Melbourne, Australia. The CSL Group of companies employs more than 20,000 people with operations in more than 60 countries. Seqirus was established on 31 July 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. It has leading R&D capabilities, a broad portfolio of differentiated products and a commercial presence in more than 20 countries. For more information visit www.seqirus.com and www.csl.com. Intended Audiences Forward-Looking Statements References SOURCE Seqirus | ||
Company Codes: Australia:CSL, OTC-PINK:CSLLY |
View original content:
